Tech Company Financing Transactions

ImmuneXcite Funding Round

ImmuneXcite, based in Lexington, secured $8.6 million from Cormorant Asset Management, Partners Innovation Fund and Sanofi-Genzyme BioVentures.

Transaction Overview

Company Name
Announced On
12/11/2015
Transaction Type
Venture Equity
Amount
$8,600,000
Round
Series A
Proceeds Purpose
ImmuneXcite plans to use the funding to complete studies that will enable selection of a lead program to advance into clinical trials.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Forbes Rd.
Lexington, MA 02421
USA
Email Address
Overview
The mAbXcite platform is ImmuneXcite's proprietary product-focused drug discovery engine that represents a fundamentally new approach in the rapidly growing field of cancer immunotherapy.
Profile
ImmuneXcite LinkedIn Company Profile
Social Media
ImmuneXcite Company Twitter Account
Company News
ImmuneXcite News
Facebook
ImmuneXcite on Facebook
YouTube
ImmuneXcite on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Eric Furfine
  Eric Furfine LinkedIn Profile  Eric Furfine Twitter Account  Eric Furfine News  Eric Furfine on Facebook
Chief Scientific Officer
Ifat Rubin-Bejerano
  Ifat Rubin-Bejerano LinkedIn Profile  Ifat Rubin-Bejerano Twitter Account  Ifat Rubin-Bejerano News  Ifat Rubin-Bejerano on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/11/2015: The Tab venture capital transaction
Next: 12/11/2015: Rhythm Pharmaceuticals venture capital transaction

 

Share this article

 


Where The Data Comes From

We record funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary